Navigation Links
Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
Date:10/26/2007

SOUTH SAN FRANCISCO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on Thursday, November 1, 2007 at 10:30 a.m. ET/7:30 a.m. PT to discuss financial results for the third quarter 2007.

Individual and institutional investors can access the call via (888) 297-0358 (U.S. and Canada) or (719) 325-2215 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media -- Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
6. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
7. Versatile Reporter Vectors for Monitoring Viral Transduction
8. In Vivo Signal Transduction Pathway Reporting Systems
9. Improved Vectors for PathDetect Trans-Reporting Systems
10. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
11. Cis-Reporting System Monitors Intracellular Calcium Mobilization

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...HOBOKEN, N.J., Dec. 2 According to...5 percent of Americans diagnosed with diabetes alr...betic retinopathy, damage to the retina caused by ... in people with diabetes and is one of the most fe...rcent of all patients who,ve had diabetes for 10 y...
(Date:12/1/2009)...CLINE VILLAGE, Nev., Dec. 1 /PRNewswire-FirstCall/...ay announced revenue guidance for the fourth quart...llion, as compared with $69 million for the fourth...results was the first of two installment payments ...ourth quarter 2008 results was a one-time $1.8 mil...
(Date:12/1/2009)..., NEW YORK, Dec. 1 Reportlinker...s available in its catalogue: ,, Industrial En...reportlinker.com/p0164431/Industrial-Enzymes---A-G... market is an oligopoly with few strong players an...t activities. Keen competition and commoditization...
(Date:12/1/2009)...LYMOUTH, Mass., Dec. 1 Harvest Tec...today results from the company sponsored 60-patien...cal Center in Chennai, India using the company,s B...ble Critical Limb Ischemia (CLI). Sri Ramachandra ...associated institution based in Chennai, India and...
Breaking Biology Technology:Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...Calif., Aug. 29 SuperGen Inc.,(Nasdaq: SUPG ), a..., rapid,development and commercialization of thera...es, today announced that James S. Manuso, Ph.D.,Pr...o present at the Thomas,Weisel Partners Healthcare...ons Hotel in Boston. SuperGen,s presentation at t...
...ce Call & Webcast Today at 10:00 CET, AMSTERDAM, ...ext: AMT), a leader in the field of human gene the... year of 2007. Highlights - Successful IPO, rais...ash equivalents of EUR 56.3 million at June 30, 20...ts from CIMA, one of,Europe,s leading gene therapy...
... is Largest and First of its Kind in Private Secto...that enhance patient safety and quality of care, C...o $1 million to fund new and innovative programs,a...linics across the,country. This grant is the large...mpany. Grants of up to $50,000 will provide fundi...
Other Biology Technology:Amsterdam Molecular Therapeutics Reports Half Year Results 2007 2Amsterdam Molecular Therapeutics Reports Half Year Results 2007 3Amsterdam Molecular Therapeutics Reports Half Year Results 2007 4Amsterdam Molecular Therapeutics Reports Half Year Results 2007 5Amsterdam Molecular Therapeutics Reports Half Year Results 2007 6Amsterdam Molecular Therapeutics Reports Half Year Results 2007 7Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care 2Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care 3
(Date:12/2/2009)...New York, NY, December 2, 2009 Commonly prescribe...t of asthma in pregnant women as well as pre-term ...m disorders, psychiatric pathology, cognitive prob..., according to a new study published in the Decemb...cs & Gynecology . , Beta 2 adrenergic agonist dr...
(Date:12/2/2009)..., (Dec. 2, 2009) HOBOKEN, NJ According to the Na...nt of Americans diagnosed with diabetes already ha...etinopathy, damage to the retina caused by leaky b...ple with diabetes and is one of the most feared di...f all patients who,ve had diabetes for 10 years or...
(Date:12/1/2009)...December 1, 2009: OptiNose is pleased to announce ...cal study investigating the efficacy and tolerabil...or the topical treatment of chronic rhinosinusitis...urnal of the International and European Rhinologic... polyps is a chronic disease that can significantl...
Breaking Biology News(10 mins):Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 3New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2Intimate abuse study finds clear links with poor health and calls for holistic primary care approach 50770 1Intimate abuse study finds clear links with poor health and calls for holistic primary care approach 50770 2Microscopic beads could help create designer immune cells that ignore transplanted organs 50768 1Microscopic beads could help create designer immune cells that ignore transplanted organs 50768 2Battle of the sexes benefits offspring says research 9115 1Battle of the sexes benefits offspring says research 9115 2
...grazing normally on algae in the rocky intertidal ... infected by a parasite. But the better news is, a...w Hampshire, that you might have more to eat if pl...h, published in this week’s Proceedings of the Nat...ww.pnas.org/papbyrecent.shtml ), suggests that par...
...ieved to be one of the detrimental effects of clim...h effective local management, according to new res...erm recovery of coral reefs in Palau and elsewhere...t and can bounce back magnificently if subjected t...pristine conditions," says Robert van Woesik, one ...
...rsity of California-Davis recently developed a mat... bacteria in the environment. Researchers believe ...king into account characteristics of the natural s...uts. This model will help scientists to quantify t...pping of genetic material between bacteria leads t...
Other Biology News:Parasites' impact goes beyond host to affect ecosystem 2Parasites' impact goes beyond host to affect ecosystem 3Palau's coral reefs show differential habitat recovery following the 1998 bleaching event 2Researchers develop way to calculate speed of bacterial sex 2
Rabbit Anti-Ferret Whole Serum Polyclonal Antibody, Unconjugated from Bethyl Laboratories
GST Expression and Purification Kit from BD Biosciences Pharmingen
...uct has been developed to significantly increase t...ns. Stability is increased at room temperature st...his product is subjected to 0.45 micron filtration...ion insures consistently high levels of activity f...
...uct has been developed to significantly increase t...ns. Stability is increased at room temperature st...his product is subjected to 0.2 micron filtration,...on insures consistently high levels of activity fo...
Biology Products: